Article Sidebar
Published:
Aug 19, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Long response to camrelizumab in metastatic lung squamous cell carcinoma with high PD-L1 expression despite EGFR G719S mutation: A case report
Abstract
Immune checkpoint inhibitors (ICIs) have been widely used in non-small cell lung cancer with wildtype EGFR/ALK genes. However, the effect of ICIs on advanced NSCLC with EGFR genes sensitive mutations has been controversial. There are no reports on whether ICIs monotherapy can be used in the treatment of NSCLC with EGFR sensitive mutations. A patient with metastatic lung squamous cell carcinoma with EGFR G719s mutations, high PD-L1 score and a tuberculosis history was given first-line treatment of afatinib, camrelizumab monotherapy (200 mg, intravenous, once every three weeks) from February 24,2020 to January 2023. The patient achieved partial response (PR) after treatment with camrelizumab. The progress-free survival (PFS) due to camrelizumab monotherapy was more than 34 months.It is concluded that camrelizumab has promising potential effectiveness as a treatment option for lung squamous cell cancer with EGFR G719 mutations and high PD-L1 score.
